The concomitant administration of antiretroviral drugs and antimalarial drugs is recommended for the treatment of HIV (Human Immunode iciency Virus) patients coinfected with malaria resulting in drug-drug interactions (DDI) causing either lack of ef icacy or toxicities. Drug metabolism is often the irst step in understanding the DDI potential of either a new chemical entity or a combination of drugs. Protease inhibitor (PI) such as ritonavir is a potent CYP 3A4 inhibitor and may interact with these antimalarial drugs that are metabolized by CYP3A4 to cause metabolism-related DDI's. Hence the present study is an attempt to evaluate the potential for a drug-drug interaction between antimalarials and antiretrovirals through invitro metabolic stability studies. Metabolic stability of antimalarial and antiretroviral drugs alone and in combination with and without ritonavir and lopinavir was evaluated using human liver microsomes (HLM). The antimalarial drugs artemether, artesunate and amodiaquine were metabolically unstable alone (% metabolism ≥ 80%) and in combination with other antimalarial drugs in HLM. Lumefantrine, atovaquone and proguanil were metabolically stable (% metabolism ≤ 30%). Antiretroviral drug lopinavir was metabolically unstable while ritonavir was moderately stable. In-vitro intrinsic clearance of antimalarial drugs artemether, artesunate and amodiaquine decreased from 106.4, 290.6 and 230 ml/min/kg to 32, 44.8 and 49.5 ml/min/kg in the presence of ritonavir. However, there was no change in the in-vitro intrinsic clearance of lumefantrine, atovaquone and proguanil in the presence of ritonavir. Lopinavir did not alter the clearance of antimalarial drugs. This study suggests that ritonavir affected the clearance of a few antimalarial drugs in HLM probably by the inhibition of CYP3A4 and indings may need to be further evaluated in clinical studies.
INTRODUCTION
The treatment of patients with a coinfection of Malaria and HIV is challenging with multiple concurrent medications, with a potential for drug interactions and overlapping toxicities. There is a signi icant risk of DDIs between HIV protease inhibitors and artemisinin-containing antimalarial regimens (Dooley et al., 2008) . The changes in exposure to antiretrovirals (ARV) or antimalarials caused by a DDI may result in either development of resistance or drug toxicity. There is a critical need for safe and effective treatment regimens for both infections. The in-vitro metabolism-based studies using HLM are used to guide possible preliminary drug interactions (FDA, 2017) . The altered clearance provides insight into the likelihood of drug-drug interactions and the requirement for clinical studies.
Metabolic stability refers to the percentage of parent compound cleared over time in the presence of a metabolically active test system such as liver microsomes, liver S9, or hepatocytes. Invitro halflife (t1/2) and intrinsic clearance (CLint) are mainly utilized to express metabolic stability (Słoczyńska et al., 2019) . It serves as a basic tool to determine the drug interaction potential of drugs. Drugs with either potent cytochrome inhibition or induction potential may in luence the pharmacokinetic characteristics of coadministered drugs. Drugs with CLint in HLM above 45 mL/min/kg are classi ied as high clearance compounds, drugs with CLint values between 15 and 45 mL/min/kg as intermediate clearance compounds, and agents with CLint below 15 mL/min/kg as low clearance compounds (Mcnaney et al., 2008) .
In HIV treatment, PIs (ritonavir) are used in highly active antiretroviral therapy regimen (HAART). Ritonavir is one of the antiretroviral drugs from the PI class used to treat HIV infection and AIDS. Ritonavir inhibits cytochrome P450 3A4 (CYP3A4) and is metabolized by CYP3A4 and CYP2D6. Among available protease inhibitors, Ritonavir carries the highest risk of causing drug interactions due to inhibition of cytochrome P450 activity (Moltke et al., 1998) .
In view of the in luence of ritonavir on CYP3A activity, its presence in antiretroviral therapy may in luence the pharmacokinetics of antimalarials, particularly because artemisinin-based combination therapy (ACT's) are metabolized by CYP3A4 (Khoo et al., 2005) . In vitro metabolism-based experiments has been used to predict pharmacokinetic interactions involving CYP3A substrates. The aim of the present investigation was to evaluate metabolic stability of antimalarial, antiretroviral drugs alone, their combinations and its in luence on DDI potential of coadministered drugs.
MATERIALS AND METHODS
Artemether, artesunate, lumefantrine, amodiaquine was provided as a gift sample from IPCA (The Indian Pharmaceutical Combine Association Limited), Mumbai India. Glenmark Pharmaceuticals Limited provided proguanil and atovaquone. Ritonavir and lopinavir was provided as a gift sample from Aurobindo Pharma, Hyderabad, India. Pooled human liver microsomes (HLM) was purchased from XenoTech, USA. Nicotinamide Dinucleotide adenine phosphate reduced (NADPH) was procured from SRL Laboratories, Mumbai, India. Magnesium Chloride, Dimethyl Sulphoxide (DMSO) and Phosphate buffer of Sigma, India were used. 2mL Deep well plates of Axygen, Mexico was used.
The HPLC grade methanol, acetonitrile and ammonium acetate were obtained from Merck Chemicals, Mumbai, India. The drug analysis was carried out using LC-MS system (ABSCIEX 3200, CA, USA), HPLC system Shimadzu (CA, USA), HPLC Gemini column C18, 5 µ column 4.6 × 50 mm internal diameter Phenomenex (CA, USA), and Eppendorf centrifuge (Chennai, Tamilnadu, India) were used for the study. (Rs, 1999) The HLM used in this study comprised of 440 pmoles/mg of total P450 and 429 pmoles/mg cyt. b5. The NADPH cytochrome c reductase activity is 156 nmol/mg protein/min. It consists of CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, 2J2, 3A4, 4A11, FMO, UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A9 UGT2B7 and UGT2B17 where the enzyme activity of CYP2C8, 3A4, and 2D6 was 2350, 4070, and 301 pmoles/(mg.min) respectively. The volume of the enzyme per vial was 0.5 ml, and the protein content was 20 mg/ml in 250 mM sucrose. The metabolic stability assay protocol was performed considering the drug solution at 1uM, protein concentration at 1mg/ml and 2.4mM of NADPH. The drugs and different drug combination evaluated are as per Table 1 . First, the metabolic stability of individual drugs were evaluated, followed by anti-malarial drug combinations. The effect of lopinavir and ritonavir on the metabolic stability of antimalarial drug combinations was evaluated. Hepatic intrinsic clearance of anti-malarial drug combinations alone and in the presence of lopinavir and ritonavir was also determined.
Methods

Metabolic Stability experiment in HLM
There were samples of 0min, 60 min and the positive control with low and high clearance drugs. All the incubations were performed in triplicates. All the components used in the reaction mixture are shown in Table 2 . The drug solution in DMSO was prepared at 5 mM. The buffer used was 0.1 M potassium phosphate pH 7.4. The protein buffer mix was prepared by spiking HLM (20mg/ml) into a buffer to obtain 1mg/ml. The reaction mixture was prepared by irst adding protein buffer mixture followed by the addition of drug into 2mL deep well plate. The plate was preincubated at 37 • C for 5min. Then the reaction was initiated by the addition of co-factor NADPH followed by incubation of reaction mixture at 37 • C for Amodiaquine ---5
Atovaquone ---6
Proguanil ---7
Ritonavir ---8
Lopinavir --- For 0min control sample, ice-cold quenching solvent was added to the protein buffer mixture containing drug followed by the addition of NADPH and was prepared in a separate plate. The contents of both 0 min and 60 min plates were shaken for 5 min and then centrifuged at 2500 rpm for 40 min at 4 • C. The supernatant was subjected for LC-MS/MS analysis.
In the metabolic stability experiments, Tolbutamide and Diltiazem at 1uM concentration were used as high and low-to-moderately stable positive controls respectively.
For intrinsic clearance, 100ul of the samples at prede ined time intervals of 0min, 15min, 30min, 45min and 60min were aliquoted and added to a plate containing 500µL of quenching solvent containing 5µM of IS mixture. Samples were mixed for 5 min and then centrifuged at 2500 rpm for 40 min. After centrifugation, a plate containing the supernatant was submitted for LC/MS/MS analysis. Quinidine at 1uM concentration was used as a positive control for intrinsic clearance experiments. All the incubations were performed in duplicates. The details of the incubation mixture is provided in Table 3 .
The composition of the buffer control sample is the same as the test item reaction mixture except that it does not have protein or HLM. This sample serves as the control to check on the stability of the drug in a buffer and to ensure that loss of drug is due to metabolism and not due to crashing of the drug in a buffer.
Instrumentation
Liquid chromatography-mass spectrometry assay (LC-MS/MS) for the quantitation of artemether, artesunate, amodiaquine, lumefantrine, atovaquone and proguanil was performed on an Shimadzu LC 20 AD system (Kyoto, Japan) coupled to an API 3200 Q trap mass spectrometer (Applied Biosystems/MDS Sciex, US) via a Turbo Ion Spray ionization (ESI) interface. The fragmentation transitions for the multiple-reaction monitoring (MRM) of drugs are as per Table 6 .
Chromatographic separation was achieved on a Gemini C18 column (50 × mm i.d, 5 µm; Phenomenex, CA, USA). The chromatography was performed at 40 • C. The mobile phase A consisted of acetonitrile and 2mM ammonium acetate (pH 3.5) (90:10, v/v) and mobile phase B 0.1% (v/v) formic acid.
Qualitative Estimation of Antimalarial drugs, 
Lopinavir and Ritonavir in metabolic stability samples and intrinsic clearance samples
The area of analyte and its corresponding internal standard were acquired using LC-MS/MS method. Positive ion multiple reaction monitoring was used for the mass spectrometric detection of all drugs except for atovaquone. The details of multiple reaction monitoring (MRM), run time, ionization mode, low rate and injection volume used for various drugs are provided in Table 6 . The ammonium adducts of artemether and artesunate showed higher intensity in response and were considered for monitoring of the analyte response.
The chromatographic separation of artesunate, amodiaquine, lumefantrine, ritonavir and lopinavir was achieved with gradient mode of separation with mobile phase delivered at a low rate of 0.7 mL/min as shown in Table 4 . Atovaquone was separated using a gradient mode of elution, as shown in Table 5 . Isocratic mode of separation was used for the elution of artemether at a low rate of 0.6 mL/min with 20%: 80% of Mobile phase B and A respectively for 2min. Where 49 is the total liver protein content in mg per gram of liver and 26gms is the average liver weight per kg body weight of a human (Projean et al., 2003) .
Data Analysis
The in vivo hepatic clearance predicted (mL/min/kg) of each drug was estimated as CL Hepatic predicted = (CL int *21)/ (CL int +21)
Where 21 refers to human liver blood low in mL per min per kg body weight of human and CL int refers to intrinsic clearance. The percent metabolism values and CL int were expressed as mean ± SD. The % metabolism and CL int of drugs and its combinations are provided in Tables 7, 8 and 9 .
RESULTS AND DISCUSSION
Metabolic Stability of Antimalarial and Antiretroviral drugs in HLM
It was observed that antimalarial drugs artemether, artesunate and amodiaquine is metabolically unstable alone where >80% of drug disappears in the reaction mixture and also in combination with other antimalarial drugs in HLM. Atovaquone, lumefantrine and proguanil were metabolically stable (≤ 30%). Among the antiretroviral drugs, ritonavir was moderately stable while lopinavir was unstable.
In vitro metabolism was measured by the disappearance of the drug at 1uM, in incubations with NADPH-forti ied human liver microsomes in comparison to 0min sample as depicted in Table 7 and Table 8 . The results from buffer samples indicate that the disappearance of a drug from protein incubated sample is not due to inadequate solubility of drugs but due to hepatic metabolism. The percent metabolism of positive controls tolbutamide and diltiazem was 8.9% and 82.7% respectively, demonstrating the validity of the experiment.
Metabolic Stability of Antimalarial drugs in HLM in the presence of Lopinavir and Ritonavir
The percent metabolism of artemether, artesunate and amodiaquine decreased from 82.9%, 100% and 96.9% to 55.7%, 83.4% and 79.9% in the presence of ritonavir. However, in the presence of lopinavir, the percent metabolism of artemether reduced to 74.5% from 82.9%, but no change was observed with artesunate and amodiaquine. There was no change in the metabolism of lumefantrine, atovaquone and proguanil in the presence of ritonavir and lopinavir Table 9 . The antimalarial drugs did not seem to affect the metabolism of ritonavir and lopinavir. The percent metabolism of positive controls tolbutamide and diltiazem was 7.1% and 87% respectively, demonstrating the validity of the experiment.
Effect of Ritonavir on the intrinsic clearance of antimalarial drugs
The in vitro intrinsic clearance and predicted in vivo hepatic clearance of artemether reduced by 3.3 fold and 1.4 fold respectively in the presence of ritonavir. For artesunate and amodiaquine, the in vitro intrinsic clearance decreased by 6.5 fold and 4.6 fold respectively while the in vivo hepatic clearance decreased by approximately 1.5 fold and 1.3 fold respectively in the presence of ritonavir. There was no change observed in in vitro intrinsic clearance and predicted in vivo hepatic clearance of lumefantrine, atovaquone and proguanil in the presence of ritonavir as shown in Table 10 . The clearance of ritonavir remained unchanged in the presence of antimalarial drugs. The clearance of positive control qunidine was 29.5 ml/min/kg validating the performance of the experiment and comparable to reported results as mentioned in the literature (Wood et al., 2017) . The log percent of drug remaining was plotted against time, as shown in Figure 1 to estimate intrinsic clearance values.
Effect of Lopinavir on the intrinsic clearance of antimalarial drugs
In the presence of lopinavir, the in vitro intrinsic clearance and predicted in vivo hepatic clearance of artemether and artesunate reduced approximately only by 1.3 fold and 1.2 fold respectively. Lopinavir did not change in vitro intrinsic clearance and predicted in vivo hepatic clearance of lumefantrine, amodiaquine, atovaquone and proguanil, as shown in Table 11 . The clearance of lopinavir remained unchanged in the presence of antimalarial drugs. The clearance of positive control qunidine was 29.5 ml/min/kg validating the performance of the experiment and comparable to reported results as mentioned in the literature (Wood et al., 2017) . The log percent of drug remaining was plotted against time, as shown in Figure 2 to estimate intrinsic clearance values.
Artemisinin-based combination treatment (ACT) is now being widely used as the irst-line treatment for Plasmodium falciparum malaria throughout the world (Dondorp et al., 2009) . Artemisinin and or its derivatives such as artemether, artesunate and arteether are short-acting antimalarials with a short half-life and hence in general combined with one or two long-acting antimalarial drugs like amodiaquine, me loquine, sulfadoxine, pyrimethamine or lumefantrine (Kerb et al., 2009) . Atovaquone coformulated with proguanil is used for prophylaxis and treatment of malaria. As per WHO recommendation, the ACTs and antiretroviral drugs (ARV) are used in the treatment of patients coinfected with HIV/AIDS and malaria (World Health Organization, 2016) .
Artemether is metabolized by CYP3A4 and CYP3A5 to its more active metabolite dihydroartemisinin (Aweeka and German, 2008) .
In vitro data provides evidence for CYP2A6 as the major metabolizing enzyme for artesunate to active dihydroartemisinin (Li et al., 2003) . The antimalarial activity of artemether and artesunate is mainly due to dihydroartemisinin. Lumefantirne is also mainly metabolised by CYP3A4 in HLM (Djimdé and Lefèvre, 2009 ). Amodiaquine metabolism to N-desethylamodiaquine involves CYP3A4, CYP2C8, CYP2C9 and CYP2D6. This metabolite is considered to determine the pharmacological activity of amodiaquine (Zhang et al., 2017) . Atovaquone combination with proguanil is used for prophylaxis and treatment of malaria where Proguanil is metabolized by CYP3A4/2C19 and elimination of atovaquone does not require metabolism (Nixon et al., 2013) .
It has been reported that ritonavir is a potent inhibitor of CYP3A4, which may play a role in the metabolism of antimalarial drugs that are metabolised by CYP 3A4 (Kirby et al., 2011) . One of the principal cytochrome P450 isoforms involved in the metabolism of ACT's is CYP3A4. CYP3A4 is the most abundant isoform of cytochrome P450 in the human liver and is responsible for the metabolism of many different drugs (Furge and Guengerich, 2006) . The ixed-dose combination of lopinavir and ritonavir in the name of Kaletra is widely used in the treatment of HIV/AIDS and is the only protease inhibitor coformulation approved by FDA in both children and adults (Croxtall and Perry, 2010) . CYP3A4 is the primary enzyme involved in lopinavir bioactivation (Li et al., 2012) .
The concomitant administration of antiretroviral drugs and antimalarial drugs results in drug-drug interactions causing either lack of ef icacy or toxicities (Giao and Vries, 2001) . Ritonavir being a potent CYP3A4 inhibitor, may interact with these antimalarial drugs that are majorly metabolized by CYP3A4 to cause signi icant concentration-related toxicities (Sulkowski, 2004) . Hence the present study is an attempt to evaluate the effect of ritonavir and lopinavir on the metabolism of antimalarial drugs by estimating the changes in metabolic stability, in vitro intrinsic clearance and predicted in vivo human hepatic clearance in HLM.
The result from the metabolic stability studies indicates that artemether, artesunate and amodiaquine is metabolically unstable either alone or in combination with other antimalarial drugs in HLM. There was a decrease in percent metabolism of artemether, artesunate and amodiaquine from 82.9%, 100% and 96.9% to 55.7%, 83.4% and 79.9% in the presence of ritonavir respectively (Table 9 ). However, in the presence of lopinavir, there was no change in percent metabolism in any of the tested drugs except for artemether where there was a modest reduction from 82.9% to 74.5% (Table 9 ). This supports the fact that ritonavir being potent CYP 3A4 inhibitor is able to inhibit the CYP 3A4 mediated metabolism of the antimalarial drugs artemether, artesunate and amodiaquine to result in decreased metabolism and increased plasma concentrations. But this may impact ef icacy since the metabolites of these antimalarial drugs are considered responsible for their antimalarial activity.
The antimalarial drugs atovaquone, lumefantrine and proguanil alone were metabolically stable in HLM and continue to show no change in percent metabolism either in combination with other antimalarial drugs or ritonavir or lopinavir. This inding suggests that enzymes other than CYP's may be involved in their metabolism or the elimination route is other than metabolism like atovaquone. No change in lumefantrine metabolic stability in the presence of ritonavir despite being metabolised by CYP3A4 is probably due to the fact that lumefantrine is absorbed and cleared more slowly.
This study has demonstrated decrease in the in vitro intrinsic clearance values of artemether, artesunate and amodiaquine by 3.3 fold, 6.5 fold and 4.6 fold respectively in the presence of ritonavir. This supports the objective of the study that Ritonavir being potent CYP 3A4 inhibitor alters the microsomal stability of antimalarial drugs majorly metabolised by CYP 3A4. However, the decrease in predicted hepatic clearance was modest (less than 1.5 fold) with these antimalarial drugs in the presence of ritonavir. The correlation of in vitro intrinsic clearance to predicted in vivo hepatic clearance was poor for metabolically unstable drugs. There was no major change in vitro clearance of lumefantrine, atovaquone and proguanil in the presence of ritonavir same as metabolic stability results (Table 10 and Figure 1 ). Lopinavir did not in luence the in vitro clearance or the in vivo hepatic clearance of antimalarial drugs suggestive of not being an inhibitor of CYP enzymes (Table 11 and Figure 2 ).
In general, among the evaluated combination of anti-malarial drugs, the metabolism of artemether, artesunate and amodiaquine mediated majorly by CYP3A4 was decreased by ritonavir. The decreased in vitro intrinsic clearance of these drugs due to CYP inhibition by ritonavir may lead to an increase in exposure of drugs and decrease in exposure of their active metabolites with impact on ef icacy.
CONCLUSIONS
In this study, ritonavir decreased percent metabolism and in vitro intrinsic clearance of artemether, artesunate and amodiaquine in HLM. The decreased metabolic clearance of these drugs might be mainly due to inhibition of the CYP3A4mediated metabolism by ritonavir. The decreased clearance of artemether, artesunate and amodiaquine results in decreased concentrations of their active metabolites and may in luence antimalarial activity. The current study has raised awareness of potential drug interactions by concomitant administration of artemether-lumefantrine, artesunate-amodiaquine with ritonavir in humans. The signi icance of these indings needs to be further evaluated in clinical studies.
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